-
Product Insights
NewGE HealthCare Technologies Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our GE HealthCare Technologies Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. GE HealthCare Technologies Inc (GE HealthCare), is a global medical device provider that designs, develops, manufactures and distributes diagnostic imaging and clinical systems; products and services for drug discovery, biopharmaceutical manufacturing, and cellular technologies; imaging agents used during medical scanning procedures; and a range of healthcare IT solutions. GE HealthCare also provides services such as performance improvement and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amivantamab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Amivantamab-vmjw...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Durvalumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tislelizumab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tislelizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tirapazamine in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tirapazamine in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tirapazamine in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tirapazamine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lunresertib in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lunresertib in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lunresertib in Gastroesophageal (GE) Junction Carcinomas Drug Details: Lunresertib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacmilimab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Gastroesophageal (GE) Junction Carcinomas Drug Details: CX-072...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – A-315 in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - A-315 in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-315 in Gastroesophageal (GE) Junction Carcinomas Drug Details: A-315...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Atezolizumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Gastroesophageal (GE) Junction Carcinomas Drug Details: Regorafenib...